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Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This
multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin
(PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS,
median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD
45mgm
 2 and paclitaxel 150mgm
 2, every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas
(43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall
response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had
disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median
overall survival (OS) 13.2 months. Grade 3–4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmar–
plantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and well-
tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS.
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Advanced soft tissue sarcomas (STSs) remain a challenging
malignancy to treat, not only because of their high clinicopatho-
logical heterogeneity but also because of their limited responsive-
ness to most chemotherapeutic agents. Almost 50% of patients
who achieve good local control will eventually relapse distantly.
Patients with advanced or metastatic STS have a dismal prognosis,
with median survival less than 1 year (Sarcoma Meta-analysis
Collaboration, 1997).
A large number of agents have been evaluated for the treatment
of advanced STS over the last 30 years, but only a handful have
shown definitive activity (Spira and Ettinger, 2002). These include
doxorubicin, ifosfamide and dacarbazine. Doxorubicin and
ifosfamide are considered the cornerstones of treatment for
advanced STS, consistently producing responses as monotherapy
in more than 20% of previously untreated patients (Pinedo and
Kenis, 1977). Most studies have demonstrated a clear dose–
response relationship for both of these drugs (O’Bryan et al, 1977,
Antman et al, 1990). Combinations of the active drugs have shown
improved response rates, but are often limited by increased
toxicity (Benjamin, 1987). Importantly, no benefit in overall
survival (OS) has yet been achieved in comparison with single-
agent doxorubicin (Edmonson et al, 1993, Santoro et al, 1995). The
demonstration of a dose–response curve for doxorubicin, led to
several investigational attempts to maximise the therapeutic index
of this drug and its combinations. The development of growth
factor support made it feasible to elevate the doxorubicin dose to
75mgm
 2 in combinations with ifosfamide, achieving much
higher response rates (Steward et al, 1993). However, numerous
reports of anthracycline–ifosfamide combinations in STS showed
that higher doses yielded higher responses, but also more toxicity,
and little, if any, change in OS (De Pas et al, 1998; Patel et al, 1998).
These results clearly indicate the need for novel approaches to
the treatment of advanced STS (Santoro, 1999). In an attempt to
increase the antitumour activity of doxorubicin and reduce its
dose-limiting toxicities, new formulations have been developed.
Pegylated liposomal doxorubicin (PLD, CAELYXt) is a liposomal
formulation of doxorubicin, sterically stabilised by coupling
segments of polyethylene glycol (PEG) onto the liposomal surface.
Thus higher doses can be delivered safely and more efficiently
(Lasic, 1996; Stewart and Harrington, 1997). This encapsulation of
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ldoxorubicin has been shown to reduce the nonspecific drug
delivery to normal tissues, and the high peak plasma levels of free
drug, both of which contribute to toxicity. The delivery of
doxorubicin to tumour sites with improved specificity may be
possible. Pegylated liposomal doxorubicin was shown to have
equivalent activity to doxorubicin and an improved toxicity profile
in experimental models and clinical studies (Gabizon et al, 1994;
Uziely et al, 1995).
Soft tissue sarcoma seems the ideal target for PLD, since the
parental drug doxorubicin is the mainstay of treatment and a clear
dose–response relationship is recognised. Several published
studies addressing the activity of PLD in STS are now available;
unfortunately not all have comparable results (Casper et al, 1997;
Chidiac et al, 2000). There are some 10 phase I/II trials reported
with single agent use of PLD in STS including a recent randomised
phase II study comparing PLD with standard doxorubicin (Judson
et al, 2001). In general, these studies indicate that PLD is well
tolerated with activity demonstrated in most cases. Recently the
data from eight initial studies were reviewed, concluding that the
activity of PLD in STS is a potential reality (Toma et al, 2000).
Although PLD was used with the aim to increase dose intensity of
doxorubicin, the doses evaluated so far, are lower than those
estimated necessary for optimal response compared to doxorubi-
cin. However, PLD has an extremely long half-life and only
comparative pharmacokinetic data can allow real comparisons of
the relative dose intensities of free and encapsulated doxorubicin.
Comparative data on the efficacy of the two formulations in STS
can be extracted by their direct clinical comparison in the
randomised EORTC phase II study (Chidiac et al, 2000). In this
study, PLD (50mgm
 2 every 4 weeks) was found to have
equivalent efficacy to doxorubicin (75mgm
 2 every 3 weeks) in
patients with advanced STS, with an improved toxicity profile.
The taxanes have different mechanisms of action and they also
appear to have single-agent activity in advanced STS (Casper et al,
1998). Docetaxel has demonstrated activity rates of 17% in
pretreated patients (van Hoesel et al, 1994; Kostler et al, 2001).
Initial studies with paclitaxel monotherapy showed activity, with
major responses seen in eight out of nine patients with
angiosarcoma (Fata et al, 1999). Another study using single agent
paclitaxel resulted in 12.5% overall response rates (ORRs)
(Balcerzak et al, 1995). Two studies evaluating paclitaxel in
combination with either Epirubicin or doxorubicin in advanced
STS, concluded that it did not increase the known activity of
anthracylines, as 20% response rates were achieved (Sandler et al,
1998; Pivot et al, 2002).
The proven synergistic activity of paclitaxel with anthracyclines
(Gianni et al, 1995), and the single-agent activity of this agent as
well as the demonstrated equivalent activity of PLD to doxorubicin
in advanced STS, constituted the rationale for the present study
performed by the Hellenic Cooperative Oncology Group. This was
a phase II study carried out to assess the efficacy and toxicity of the
combination of PLD and paclitaxel as first-line treatment in
patients with locally advanced or metastatic STS.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed advanced STS, o75 years of
age, Eastern Cooperative Oncology Group (ECOG) performance
status (PS) p2 and evidence of measurable or evaluable disease
were eligible. No previous chemotherapy for advanced disease was
allowed. Previous adjuvant or neo-adjuvant treatment with an
anthracycline-containing regimen was allowed provided that there
was at least a 12-month treatment-free interval. Adequate
haematological, renal and hepatic functions were required (WBC
43.5 10
9l
 1, platelets 4100 10
9l
 1, bilirubin o1.2mgdl
 1,
SGPT, gGT, alkaline phosphatase normal, creatinine o1.4mgdl
 1
or creatinine clearance 470mlmin
 1). Pregnant patients or those
with other malignant tumour or tumour history, except for
nonmelanoma skin cancer or radically excised carcinoma in situ of
the uterine cervix, were excluded. Furthermore, patients with an
active infection or other serious medical or mental condition,
which would impair their ability to receive protocol treatment,
including prior allergic reactions to drugs containing cremophor,
were not eligible. Exclusion criteria also included neurological
disorders or pre-existing motor or sensory neurotoxicity grade
X2. Furthermore, gastrointestinal stromal tumours (GIST) were
excluded, while all other STS histologies were allowed. The study
was conducted according to the Declaration of Helsinki and the
Guidelines for Good Clinical Practice. The Scientific Committee of
the Hellenic Cooperative Oncology Group approved the study, and
informed consent was obtained from all patients prior to study
entry. Ethical approval was provided by local Institutional Review
Boards in participating institutions and centrally granted by the
HECOG Protocol Review Committee, according to the Group’s
bylaws.
Treatment schedule
Treatment was administered on an outpatient basis. Pegylated
liposomal doxorubicin of 45mgm
 2 was administered by an
intravenous infusion over 30min on day 1, followed by paclitaxel
150mgm
 2 as an intravenous infusion over 3h, on day 1. Cycles
were repeated every 28 days. All patients received standard
premedication prior to paclitaxel administration, in order to
prevent hypersensitivity reactions. Standard antiemetic premedi-
cation and treatment was also administered. Haematopoietic
growth factors were not used prophylactically. Patients received
a total of six cycles unless disease progression or unacceptable
toxicity occurred.
Dose modifications
Toxicity was evaluated before each treatment cycle according to
the National Cancer Institute Common Toxicity Criteria (NCI CTC
version 2.0). Chemotherapy courses were given on schedule
providing that ANC was X1.5 10
9l
 1 and the platelet count
X100 10
9l
 1. If ANC o1500 or PLT o100 on day 1, treatment
was delayed for 1 week. If blood count did not recover after 3
weeks, the patient was considered off protocol. Both drug doses
were reduced by 25% in case of grade 3–4 myelotoxicity or
neutropenic fever. In case of grade 3–4 neutropenia during a
chemotherapy cycle, haematopoietic growth factor (G-CSF)
5mgkg
 1 was used prophylactically on days 7–12, for all
subsequent cycles. For any major organ toxicity grade 42,
treatment was discontinued. In case of symptomatic arrhythmia,
AV block (except first degree), or other heart blocks, paclitaxel
infusion was stopped; the patient received treatment and was taken
off protocol. Furthermore, for any hypersensitivity reaction
paclitaxel infusion was interrupted. Following treatment for the
reaction, paclitaxel infusion was reinitiated slowly with close
attendance. If a severe reaction reoccurred treatment was stopped.
In case of palmar–plantar erythrodysesthesia (PPE) treatment was
interrupted until resolution of symptoms. If symptoms persisted
for more than 4 weeks treatment was discontinued.
Efficacy evaluation
Baseline evaluation included a complete past medical history
focusing on heart, lung, and kidney function; physical examina-
tion; computed tomography (CT) scans of the chest, abdomen and
pelvis; bone scan; complete blood counts; and renal and liver
function tests. Evaluation during treatment included CBC, renal
and liver function tests obtained before each course. CBC was also
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lobtained on day 14 of the first course in order to assess nadir WBC
and PLT. Tumour evaluation was repeated after three courses and
at completion of treatment. Dose intensity was defined as the total
amount of the drug given (mgm
 2) per week. Standard WHO
criteria were used to assess response. Follow-up disease evaluation
was performed at 3 monthly intervals following the end of
treatment. As response was the primary end point, all responses
from participating institutions were centrally reviewed by a
radiologist not participating in the study. All patients were
analysed for efficacy on an intention-to-treat basis. All patients
receiving at least one cycle of chemotherapy were analysed for
toxicity. All adverse events resulting in discontinuation of study
drug were followed closely until resolution or stabilisation.
Patients were followed every 3 months after the completion of
treatment.
Statistical analysis
The study was a nonrandomised, phase II study. The primary end
point was objective response rate and secondary end points were
OS, time to progression (TTP) and toxicity. The sample size was
calculated on the assumption that a 40% response rate would be
detected and the minimum acceptable response rate would be 20%.
According to Simon’s two-stage design, a sample of 18 patients was
required in the first step. If a minimum of five responses were
observed a total of 33 patients would be accrued. Thereby, if at
least 11 responses occurred the probability of accepting a
treatment with a real response rate of less than 20% would be
5%. On the other hand, the risk of rejecting a treatment (at the
second stage) with a response rate of more than 40% would be
20%. Time to progression was calculated from the initiation of
treatment to the date of progression of the disease was firstly
documented (patients who discontinued their treatment for any
reason or died from disease-related causes were considered, at that
time, as having disease progression). Survival was calculated from
initiation of treatment to the date of last contact or to the date of
death. The Kaplan–Meier method was used to calculate TTP and
survival curves (Kaplan and Meier, 1958). Data analysis was
performed using the computerised statistical package SPSS version
10.0.
RESULTS
Patient characteristics
Between January 1998 and October 2001, 42 patients with locally
advanced or metastatic STS were enrolled into the study. The main
patient baseline characteristics are summarised in Table 1. Patient
age ranged from 18 to 78 years, with a median age of 54 years.
Median ECOG PS was 1 (range, 0–2). Primary disease sites were
visceral in 43% of cases (gastrointestinal tract, 12%; lungs; 7%;
uterus, 24%), in extremities (19%), retroperitoneal (12%), and
other (26%). Half of the patients (50%) had undergone complete
surgical excision of primary disease, while 36% had received
postsurgical radiotherapy and 21% had received adjuvant che-
motherapy. The adjuvant regimens used were mainly anthracycline
based (doxorubicin monotherapy in one case, epirubicin mono-
therapy in two cases, ifosfamide monotherapy in three cases and
combinations of ifosfamide–doxorubicin in three cases). In all
cases adjuvant chemotherapy was completed more than 1 year
prior to study entry. Concerning disease extent at study entry, 31%
of patients had only locally advanced disease, while 69% had
distant disease (lungs, 43%; liver, 14%; lymph nodes, 10%; bones,
2%), with multiple site involvement (more than one metastatic
site) in 40%. Characteristics of primary and metastatic disease are
shown in Table 1. The majority of patients (67%) presented with
symptomatic disease at study entry, while significant weight loss
(410%) was reported in only 5% of the patients at study entry.
The most common histological types included leiomyosarcomas
(43%), malignant fibrous histiocytomas (14%) and liposarcomas
(12%). The primary lesion was reported as 45cm in size in 71% of
the cases, while the histological grade of the primary lesion was
42 in 30% of the cases. Details of histology, differentiation and
size of primary disease are shown in Table 2.
Response and survival
From a total of 42 patients included in the analysis, six (14%) were
not evaluable for response but were included as nonresponders
according to an intention-to-treat analysis. One patient (2%)
refused to start treatment, while five patients (12%) discontinued
treatment prior to response evaluation (following the first
treatment cycle, two patients discontinued due to disease
progression, two more patients refused to continue due to toxicity
and withdrew consent while a further patient moved to different
hospital care and also withdrew consent). Seven patients achieved
an objective response, for an ORR of 16% (95% CI 7–31.4),
including one complete response (CR 2%, 95% CI 0.06–12.6) and
six partial responses (PRs 14%, 95% CI 5.4–28.5). In addition, 14
patients had disease stabilisation (SD 33%, 95% CI 19.6–49.6), and
15 patients had progressive disease (PD 36%, 95% CI 21.6–52).
Table 1 Patient characteristics
Patients
Characteristic No. %
Number of patients included in final analysis 42
Age (years)
Median (range) 54 (18–78)
Sex
Male 16 38
Female 26 62
ECOG performance status
01 5 3 6
12 4 5 7
23 7
Median 1
Treatment of primary disease
Complete surgical excision 21 50
Postsurgical radiotherapy 15 36
Adjuvant chemotherapy 9 21
Site of primary disease
Visceral 18 43
Gastrointestinal 5 12
Lung 3 7
Uterus 10 24
Extremities 8 19
Retroperitoneal 5 12
Other 11 26
Site of metastatic disease
a
Locally advanced disease 26 62
Metastatic disease 29 69
Lung 18 43
Liver 6 14
Lymph nodes 4 10
Bone 1 2
4One metastatic sites 17 40
aPercentages exceed 100% since some patients have more than one metastatic site.
ECOG¼Eastern Cooperative Oncology Group.
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lWith a median follow-up of 41.5 months (range, 0.56–51.6
months), the median TTP was 5.7 months (range, 0.56–51.6
months; 95% CI 3.06–8.4). Disease progression was reported in 36
patients. The median OS for all patients was 13.2 months (range,
0.6–51.6 months; 95% CI 8.56–17.87). Time to progression and OS
curves are shown in Figure 1.
Study treatment and toxicity
A total of 164 treatment cycles were administered. Patients
received a median number of four cycles of chemotherapy, with
a range of cycles. Of the 42 patients entered, 16 patients (38%)
completed treatment, while 26 patients (62%) discontinued
treatment due to disease progression, toxicity, or other reasons.
The majority of treatment cycles were administered with full dose
of paclitaxel (90%) and full dose of PLD (82%). The median
duration between cycles was 28 days (range, 21–49). Haemato-
poietic growth factor (G-CSF) support was required for 54% of the
patients. The median relative dose intensity for paclitaxel was 0.99
(range, 0.7–1.0), and for PLD was 0.95 (range, 0.7–1.0).
All patients were evaluable for toxicity. Grade 3 haematological
toxicities included neutropenia (12%), anaemia (15%) and
thrombocytopenia (2%). Five percent of patients experienced
grade 4 neutropenia, with one febrile neutropenic episode
requiring hospitalisation. Other grade 3 toxicities included
neurotoxicity (5%), PPE (7%), stomatitis (5%) and allergic
reaction (2%). There was one episode of exfoliative dermatitis
(grade 4, 2%) and one episode of severe mucositis (grade 4, 2%).
Total alopecia was noted in 72% of patients. Other nonhaemato-
logical toxicities were mild. There were no treatment-related
deaths. Detailed toxicity data according to the NCI CTC criteria are
presented in Table 3.
DISCUSSION
The present study is the first to report on the efficacy and toxicity
of a PLD-based combination in advanced STS, incorporating
another new agent, paclitaxel. The response rates seen in our study
are comparable to those of single-agent doxorubicin (Dirix and
van Oosterom, 1999) and are definitively improved from those
reported in PLD studies until now (Chidiac et al, 2000). Seven
patients achieved objective responses, including one complete
response, and a median TTP for responders of almost 6 months
(TTP, 5.7 months; range, 1–52 months). In all, 15 patients
progressed during treatment, while the remaining 14 patients
achieved meaningful disease stabilisation. The median survival
time was 13.2 months (range, 0.6–51.6 months), which compares
to the highest survival times reported with standard regimens in
advanced STS.
The doses and schedule of administration of the two drugs in
our study were identified from previous phase I/II experience of
our group and others (Briasoulis et al, 1999, Gogas et al, 2002).
Although there is considerable experience with the combination of
doxorubicin and paclitaxel, data regarding the use of PLD and
taxanes are limited. Most studies in other tumour types where this
combination has been evaluated, utilise paclitaxel at doses of
Table 2 Histological characteristics of primary disease
Histological types N %
Leiomyosarcoma 18 43
Malignant fibrous histiocytoma 6 14
Liposarcoma 5 12
Mixed mu +llerian tumour 2 5
Malignant schwannoma 2 5
Neurofibrosarcoma 2 5
Synovial sarcoma 2 5
Chondrosarcoma 1 2
Malignant mesenchymoma 1 2
Epithelioid sarcoma 1 2
Unclassified 2 5
Grade
I6 1 4
II 10 24
III 17 40
Unknown 9 22
Size of primary lesion
p5cm 7 17
45cm 30 71
Unknown 5 12
Months
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Figure 1 Time to progression (----) and OS (—) of 42 patients with
advanced STS treated with PLD/paclitaxel combination. Median Follow-up:
41.5 months, median survival: 13.2 months, events/total: 36/42, median
TTP: 5.7 months.
Table 3 Treatment-related toxicity
N (%)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Anaemia 9 (22) 6 (15) 6 (15) —
Leukopenia 5 (12) 6 (15) 7 (17) 2 (5)
Neutropenia 2 (5) 4 (10) 5 (12) 2 (5)
Thrombocytopenia — — 1 (2) —
Infection 2 (5) 1 (2) — 1 (2)
Gastrointestinal (N/V) 10 (24) 1 (2) — —
Alopecia 2 (5) 30 (72)
Neurotoxicity 5 (12) 3 (7) 2 (5) —
Allergic reaction 1 (2) 1 (2) 1 (2) —
Mucositis 4 (10) 3 (7) 1 (2) 1 (2)
Stomatitis — 1 (2) 2 (5) —
PPE 1 (2) 1 (2) 3 (7) 1 (2)
Febrile neutropenia occurred in one patient (2%). There were no treatment-related
toxic deaths.
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l175mgm
 2 combined with 30–35mgm
 2 PLD, administered
every 3–4 weeks (Briasoulis et al, 1999; Dirix and van Oosterom,
1999; Gogas et al, 2002). We opted for a higher dose of PLD
(45mgm
 2) combined with paclitaxel at 150mgm
 2, and admin-
istration every 4 weeks, which has been shown to be the optimal
time schedule for such doses with regard to skin toxicity. The
above schedule exhibited a similar toxicity profile to reported
combinations of paclitaxel–PLD in other tumour types (Briasoulis
et al, 1999; Dirix and van Oosterom, 1999; Gogas et al, 2002). There
was no grade 3 or 4 gastrointestinal toxicity, while myelosuppres-
sion was acceptable, with only one case of febrile neutropenia
requiring hospitalisation. Skin and mucosal toxicities are the most
frequent and prevalent toxicities of PLD administration. Similarly,
these were the most common nonhaematological toxicities of the
combination of PLD with paclitaxel in this group of patients, with
7% of patients experiencing grade 3 PPE and one patient
discontinuing treatment due to exfoliative dermatitis. However,
the incidence of marked skin toxicity observed in our study, is
significantly lower than that usually reported when lower doses of
PLD (35mgm
 2) are administered in shorter time intervals, every
3 weeks (Gogas et al, 2002). The addition of paclitaxel to the higher
dose of PLD used in our study did not seem to affect the incidence
of skin toxicity, as this is possibly related to the dose scheduling
intervals and exposure to persistent drug levels (Lyass et al, 2000).
There was no apparent cardiac toxicity observed in our cohort of
patients. A 5% occurrence of grade 3 neurotoxicity, seen here, is
consistent with other studies using similar doses of paclitaxel
(Mavroudis et al, 2002). The administration of this regimen at the
selected doses allowed for a successful delivery of the scheduled
dose intensity.
The favourable prognostic factors for response to chemother-
apy, as studied by the EORTC Soft Tissue and Bone Sarcoma
Group, include young age, high grade, absence of liver metastases
and liposarcoma histology (van Glabbeke et al, 1999). Our study
included all STS histologies, no GIST, and a large majority of
leiomyosarcomas (43%). The high proportion of leiomyosarcomas
could account for the relatively low response rates obtained in our
study, as some series suggest that this histological type is more
chemoresistant than other STSs. The median age was that reported
in most studies with STS (54 years), however, patients as old as 78
years of age were treated. The majority of patients (43%) had a
visceral site of primary disease, with only 19% of primary
extremity sites. A total of nine patients had received adjuvant
chemotherapy after resection of primary disease, which was mainly
anthracycline based. Although in all cases there was more than a
12-month interval between adjuvant chemotherapy and study
treatment, previous exposure to anthracycline could lead to
resistance and account as well for the relatively low response rates
seen. Furthermore, at study entry, a high proportion of patients
had distant metastatic disease (69%) with the commonest site
being lungs (43%), however, 14% of the patients had liver
involvement, which is considered an unfavourable prognostic
factor for response, while more than one-third of the patients had
extensive disease with multiple site involvement. This could
possibly explain the lower than anticipated response rate seen in
this study. As discussed by several investigators, the only way to
avoid the large differences in response seen among studies in STS,
is to focus on better stratification of patients with advanced STS
according to prognostic factors.
In conclusion, the results of this study indicate that the novel
combination of PLD with paclitaxel is a safe and well-tolerated
regimen, demonstrating modest efficacy as first-line therapy in
patients with advanced STS. Although the role of chemotherapy
dose intensity in advanced STS is not fully established, it seems
critical to combine the few active drugs at adequate doses and
optimal schedules. Efforts to refine the currently available
therapeutic options for patients with advanced STS in order to
maximise the therapeutic index should continue together with
basic research identifying critical targets and pathways for
therapeutic intervention.
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